Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Registration Number
- NCT00335647
- Lead Sponsor
- Immune Control
- Brief Summary
RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and to see how well it works in treating patients with refractory advanced multiple myeloma.
- Detailed Description
OBJECTIVES:
* Determine the safety of high-dose fluphenazine hydrochloride in patients with refractory advanced multiple myeloma.
* Determine the pharmacological properties of this drug.
* Determine the effectiveness of this drug in these patients.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive high-dose fluphenazine hydrochloride IV 3 times on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of patients receive escalating doses of fluphenazine hydrochloride until the maximum tolerated dose is determined.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy Safety
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Hackensack University Medical Center Cancer Center
🇺🇸Hackensack, New Jersey, United States
Long Island Jewish Medical Center
🇺🇸New Hyde Park, New York, United States
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Hackensack University Medical Center Cancer Center🇺🇸Hackensack, New Jersey, United States